
Jeffrey Bishop, Interim Vietnam Country Manager, Takeda (L), and Assoc. Prof. Dr. Tran Thi Thanh Huong, Director of the Bright Future Fund (R) at the signing ceremony for the partnership agreement between two organizations for the initiative to support blood cancer patients in 2023
Hanoi, (VNA) - ♋Hematopoietic system cancer (a.k.a. blood cancer) is one of the most dangerous types of cancer with complicated developments. The patients can face a high risk of serious complications leading to death if the disease is not detected early and treated promptly.
A survey conducted in 2022 with blood cancer patients at Vietnam National Cancer Hospital, National Institute of Hematology and Blood Transfusion, and Blood Transfusion and Hematology Hospital in Ho Chi Minh City revealed that 48% of surveyed patients are in the age group of 21-40 years old (accounting for the highest patient rate), 10% of patients are under 20 years old and 16% of patients are over 40 years old. Many patients with blood cancer said they still suffer from a lack of information and knowledge about the disease. According to the survey findings, 86% of patients want more information and knowledge from experts and doctors via face-to-face and online sessions. In comparison, 60% want to gain more information through experience sharing and exchanging with other patients.Assoc. Prof. Dr. Tran Thi Thanh Huong, Director of the Bright Future Fund, highly appreciates Takeda's positive support that has enabled the fund to continue supporting cancer patients in Vietnam in general and blood cancer in particular. “Accompanying blood cancer patients will pave the way for a long-term partnership between the two sides in guiding and sharing knowledge to help patients easily monitor, detect early symptoms, and exchange information with healthcare professionals. From there, it will help alleviate some of the difficulties that patients are experiencing, such as declines in physical and mental health,” said Dr. Huong.
Ms. Mai Thanh Binh, Takeda Vietnam's Market Access Lead, said, “Takeda Vietnam is committed to partner with the Bright Future Fund in empowering patients with lymphoma through knowledge. We hope that the continuous collaborations will serve as a meaningful knowledge playground for blood cancer patients, where doctors can answer patients' questions and learn more about their needs. That leads to improve the treatment quality as well as quality of live for patients with blood cancer.”/.